𝗦𝘂𝗴𝗴𝗲𝘀𝘁𝗲𝗱 𝗥𝗲𝘃𝗲𝗿𝘀𝗮𝗹 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗲𝘀 𝗼𝗳 𝗢𝗿𝗮𝗹 𝗔𝗻𝘁𝗶𝗰𝗼𝗮𝗴𝘂𝗹𝗮𝗻𝘁 𝗨𝘀𝗲 𝗳𝗼𝗿 𝗠𝗮𝗷𝗼𝗿 𝗕𝗹𝗲𝗲𝗱𝗶𝗻𝗴 𝗮𝗻𝗱 𝗯𝗲𝗳𝗼𝗿𝗲 𝗘𝗺𝗲𝗿𝗴𝗲𝗻𝗰𝘆 𝗦𝘂𝗿𝗴𝗲𝗿𝘆.
As shown in Panel A, reversal management depends on the urgency of surgery or the invasive procedure. Reversal management includes administration of oral or intravenous (IV) vitamin K with or without 4F-PCC, depending on the timing of the procedure (emergency or urgent), baseline international normalized ratio (INR) value, and presence (or absence) of active bleeding. For patients receiving direct oral anticoagulants (DOACs), the decision also depends on time to surgery. Decision making is informed by DOAC type, time since last dose, half-life, presence (or absence) of active bleeding, and renal function tests to estimate residual drug activity.
Panel B shows reversal strategies for patients presenting with major bleeding while receiving an oral anticoagulant. The reversal strategy of vitamin K antagonists includes vitamin K given intravenously or orally, combined with 4F-PCC and INR testing. Management of anticoagulant reversal of direct oral FXaIs is based on four key factors (shown as the 4Ts): type of bleeding, timing of the last dose, thrombotic risk, and need for invasive procedures in the next 48 hours that would result in the administration of UFH. These factors may facilitate the use of specific (e.g., andexanet alfa) or nonspecific (e.g., 4F-PCC) antidotes. The reversal of dabigatran is informed by three clinical variables (shown as the 3Rs) — the type of bleeding, time of the last dose of dabigatran, and preserved renal function.
Learn more in the Review Article “Antidotes for Anticoagulation Reversal” by Bianca Rocca, MD, PhD, and Hugo ten Cate, MD, PhD: https://t.co/XobqwMebfy
NEJM subscribers: Explore this article deeper with AI Companion.
The ASN journals, #ASNCJASN, #ASNJASN, and #ASNKidney360, recognize and honor the outstanding work of junior colleagues in their early stages of nephrology careers by awarding Trainee of the Year awards. Learn more about the opportunity here: https://t.co/qnwY2vzSr6
🔆Need to standardise HDF practice & promote wider adoption across 🇮🇳 subcontinent
🔥survival benefit, lower CV complications, lower IDH, better QOL
🔗 https://t.co/C9fCdDxs4N
💥Do you know how René Laennec invented 🩺⁉️
🔥He was a French Physician & musician, skilled in carving wooden flute
🔆First Stethoscope was a 25x2.5cm hollow wooden cylinder
🔆Coined term “Stethoscope"
Greek: στήθος (stethos-chest) + σκοπός (skopos-examination)
Pic-Wiki
#FOAMed #MedTwitter #MedEd #Medicine #medstudent
🔆Need to standardise HDF practice & promote wider adoption across 🇮🇳 subcontinent
🔥survival benefit, lower CV complications, lower IDH, better QOL
🔗 https://t.co/C9fCdDxs4N
🎥Watch Dr Ozge Hurdogan present the CKJ publication:
Clinicopathologic features and outcomes of patients with DNAJB9 positive fibrillary glomerulonephritis
https://t.co/Ps1VvBgSX2
PREVENT-CVD better predicts combined cardio-kidney outcomes in CKD than traditional risk scores, according to #ASNCJASN study. Adding albuminuria boosts performance, highlighting its value for integrated cardio-renal risk assessment. https://t.co/Hweipj78xG
Association between nephrolithiasis and kidney disease progression in patients with autosomal dominant polycystic kidney disease: a prospective cohort study
https://t.co/UMHrF5ndU8
Special Collection: These articles highlight recent research published in AJKD on developments in kidney transplantation and its impact on donors and recipients.
https://t.co/AR5OVuGPp7 (FREE until August 20, 2026)
This core curriculum by @LauraAponteBe & Sherry G. Mansour reviews the physiology of exercise on kidney function and provides evidence-based strategies for patient counseling and risk reduction:
https://t.co/80j7lqvq6j (OPEN ACCESS)
@YaleNephrology